Starting July 1, Zepbound will no longer be preferred on CVS Caremark’s standard formulary, while Wegovy and other anti-obesity medicines will be, according to the company. The change means that ...

CVS said Caremark will offer Wegovy at "a more affordable ... investors worried about direct competition in the market between Zepbound and Wegovy. Lilly executives remained unfazed about the ...

CVS Caremark decided to stop offering Zepbound in favor of Wegovy for weight loss. It’s the latest example of limits imposed by insurance that disrupt treatments for patients. By Rebecca Robbins ...

During the AMA, one user asked: “Are you still negotiating with CVS over Zepbound coverage? Is it possible that it will be offered again in the future under Caremark plans?” Lilly’s Pacheco ...

Evernorth said that through direct negotiations with Novo Nordisk and Eli Lilly, patients’ monthly copay costs for Wegovy (semaglutide) and Zepbound (tirzepatide) will not exceed $200. Wegovy has a ...

Patients with obesity can now get Zepbound’s strongest doses for a flat rate through Lilly’s self-pay pharmacy.

Earlier this month, CVS Caremark announced that it will now cover Wegovy under its pharmacy benefit plans — but it will no longer cover Zepbound. A study published in the New England Journal of ...

over Eli Lilly’s competing therapies Mounjaro and Zepbound. Traders scrambled on the news, with Eli Lilly’s stock declining in response, but the significance of the CVS Caremark decision has ...

This month, CVS Caremark announced that it had also signed a deal to make Novo Nordisk’s Wegovy its preferred GLP-1RA starting in July, which concurrently deprioritised coverage for Zepbound.